Differential Proteomic Analysis of DEN-Induced Hepatocellular Carcinoma in Male and Female Balb/c Mice Reveals Novel Gender Specific Markers

*Salmma Salamah Salihah[1], Muhammad Tahir[2], Bareera Bibi[3,] Rabia Sultan[4], Martin R. Larsen[2], Munazza Raza Mirza[4], Sana Mahmood[1], Muhammad Rizwan Alam[5], *Asma Gul[1]

[1] Department of Biological Sciences, International Islamic University Islamabad, Islamabad, Pakistan

[2] Biomedical Mass Spectrometry and Systems Biology, University of South Denmark, Odense, Denmark

[3] School of Interdisciplinary Engineering & Science (SINES), NUST, Islamabad, Pakistan

[4] Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan

[5] Cell Biology Laboratory, Department of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan

Corresponding Author: Salmma Salamah Salihah and Asma Gul

Authors' Disclosures

The authors declare no potential conflicts of interest.

ABSTRACT

Hepatocellular carcinoma is one of the leading causes of death with a higher prevalence in males compared to females due to distinct progression and pathogenesis patterns in both genders. This study aimed at creating, characterizing, and proteome profiling, a DEN-induced HCC model of male and female Balb/c mice. Proteins were extracted from characterized mouse models and subjected to mass spectrometry and subsequent bioinformatics analysis. The results revealed that the differentially enriched signaling pathways in treated female mice mainly belonged to the constituent of cytoskeleton, and mitochondria, including metabolic and oxidoreductase activity clusters. The enriched signaling pathways in treated male mice were related to translation, ribosomal structural and binding subunits and mRNA binding, metabolic processes, glutathione transferase activity, oxidoreductase activity, and mitochondrial activity. Protein-protein interaction analysis revealed the top ten genes ranked by highest maximal clique centrality. Survival Analysis using UACLAN indicated that among the hub genes of DEN-treated female mice, only the upregulation of NDUFA8 was associated with patient survival. In DEN-treated male mice downregulation of EEF2 and upregulation of RPL7A, RPL18A, RPL27A, RPS3, RPS 11 and

SERBP1 was associated with poor survival. The study indicates that the protein families
associated with poor survival, ribosomal and RNA binding proteins in males, and
mitochondrial complex 1 proteins in females are novel gender-specific prognostic markers
and therapeutic targets for HCC.

Key Words: Hepatocellular Carcinoma, Proteomics, DEN induced mouse model, Mass
Spectrometry, Prognostic Biomarkers

40 Introduction

Hepatocellular carcinoma (HCC) accounts for 80-90% of liver cancer cases, making it
the most common type of hepatic malignancy (Llovet et al., 2021). It poses a serious burden
on global health and the economy, especially in Asia (Kulik & El-Serag, 2019). HCC has a low
five-year survival rate of approximately 18%. It is the third leading cause of cancer-related
deaths worldwide (Siegel et al., 2022) and the second leading cause in Asia (Kim, 2024).
Liver cancer, including cholangiocarcinoma and HCC, has been ranked as the second major
contributor to cancer-related loss of lives globally from 2005-2015, with an increase of 4.6%
in absolute years of life lost (El-Serag, 2012; Tang et al., 2018). Approximately 80% of HCC
cases are concentrated in Eastern Asia and Sub-Saharan Africa consistent with the higher
incidences of chronic hepatitis B virus in these regions (Kim, 2024).

HCC is more prevalent in males compared to females, with a ratio of 4:1 (Park et al.,
2015). Females are also associated with a better survival rate compared to their male
counterparts with HCC (Lam et al., 2005). Despite the established etiological variation in
chronic liver disease, the disparity in the prognosis and characteristics of HCC between
genders remains poorly understood (Liou et al., 2023). Sex hormones, including androgens
and estrogens, play roles in HCC risk and progression. (Ito and Nguyen, 2023).

Various animal models are used to study HCC, including gene editing, in-situ
transplantation, and chemical induction (He et al., 2015). However, the first two methods
are limited in their ability to capture only a specific aspect of the tumor, hence missing the
broader clinical picture of tumor progression and immune dysregulation (Brown et al., 2018;
Liu et al., 2022). Diethyl nitrosamine (DEN) is a potent liver carcinogen used to induce HCC
by causing DNA ethylation, and genetic mutations, and ultimately leading to the
transformation of normal hepatocytes into cancer cells following a single dose (Santos et al.,
2017). DEN is activated by cytochrome P450, leading to the formation of DNA adducts and at
the same time generation of reactive oxygen species (ROS) which cause DNA damage,
oxidative stress, and eventually HCC (Memon et al., 2020). The DEN-induced mouse model
closely replicates gene expression signatures of human poor prognosis HCC and hence
showcases similar low β-catenin levels, high proliferation, chromosomal instability,
ubiquitination, and apoptosis (Li et al., 2004; Kamino et al., 2011; Wang et al., 2012).

Due to the heterogeneous nature of HCC, the development of gender-specific animal
models and their molecular characterization is of prime importance in preclinical studies.
Although the proteomic profile of DEN and CCl_4-induced HCC in mouse models has been
studied, the gender-dependent nature of HCC means that genomic, transcriptomic, and
proteomic data for either gender alone does not suffice to represent the differential
proteomic landscape. This creates an urgent need for comparative protein profiling of DEN-
induced HCC in male and female mouse models.

In this study, a DEN-induced HCC model was used, characterized, and subjected to
proteome profiling. The study provided significant proteomic data that helped in
understanding the differential expression patterns of DEN-induced HCC at the protein level
in Balb/c mice.

Materials and methods

Mouse model and tissue collection

Animals were obtained from the National Institute of Health, Islamabad, Pakistan.
The protocol was approved by the Ethical Committee, of the International Islamic University
Islamabad. The animals were treated in accordance with the guidelines of the ethical
committee. A total of 20 Balb/c mice at four weeks of age(17g body weight) were
maintained in constant 12 h light/dark cycles and temperature-controlled conditions (22-
25°C). They were fed with a standard mouse diet and water ad libitum. Balb/c mice were
divided into treatment and control groups. Each group was further comprised of five male
and six female mice. The animals from the experimental group were intraperitoneally
treated with DEN (Sigma-Aldrich, USA) (100mg/kg) at four weeks of age. Animals from the
control group were treated with solvent (normal saline) at the same age. Both treatment
and control groups were followed till 32 weeks. After the completion of the experimental
period surviving mice were terminally anesthetized by an overdose of Sodium pentobarbital,
and then sacrificed to harvest liver tissue from both treatment and control groups. The
excised liver tissue was rinsed with PBS and macroscopically evaluated for lesions/nodules
before dividing into two sections. One of the sections was fixed with 4% formaldehyde for
histological analysis and immunohistochemical staining analysis while the other section was
used for proteomic profiling.

H&E staining & immunohistostaining

Formaldehyde-fixed tissues were embedded in paraffin and sectioned. Liver tissue
sections (5μm) from both tumor and non-tumor areas were mounted on glass slides and
deparaffinized with three successive xylene treatments. Sections were hydrated through
successive treatments with 100, 95, and 70% ethanol and stained with 100% Mayer's
Hematoxylin-5 min and counterstained with Eosin. The sections were then dehydrated with

70, 95 and 100% ethanol respectively followed by Xylene treatments. Stained sections were
mounted using Permount and allowed to dry before microscopic examination.

For immunohistochemistry an antigen-retrieval method based on microwave
pretreatment and 0.01 M sodium citrate buffer (pH 6) was used as previously described
(Maffini et al., 2001). Antibodies, including anti Ki67 antibody (Cat # PA0118, Leica
biosystems), Vimentin (Cat # NCL-VIM-V9, Leica biosystems) and E-Cadherin (Cat# PA0387,
Leica biosystems) were used at 1:400, 1:1000, 1:1000-4000 dilutions, respectively. The
antigen- antibody reaction was visualized using the streptavidin-peroxidase complex, with
diaminobenzidine tetrahydrochloride (Sigma-Aldrich) as the chromogen. Counterstaining
was carried out with Harris' hematoxylin. Images were captured with an Olympus BX53
microscope equipped with Olympus digital camera.

Sample preparation for proteome analysis

118   Liver sections were rinsed with PBS and immersed in freshly supplemented RIPA
119 buffer (10 mM Tris-HCl, 140 mM NaCl, 0.1% SDS, 1% Triton X 100, and 0.01% Sodium
120 deoxycholate). The tissues were homogenized on ice for 20 minutes using a tissue
121 homogenizer. After centrifugation (13, 000× g; 20 min, 4 °C), supernatants were stored at -
122 80°C. Protein estimation was performed through Bradford Assay.

Tryptic digestion

For the enzymatic digestion of protein standard (α-casein, β-casein, and ovalbumin)
and protein samples, 0.1mg/mL(200μL) was aliquoted. To adjust the pH (~8) 1M NH4HCO3
(160μL) was added to the aliquots. Protein samples were reduced and denatured by adding
45 mM DTT and 40 mM nOGP. Afterward, the vials were incubated on a thermomixer
(Eppendorf, Germany) for 30 mins at 90°C and 800 rpm. Protein solutions were allowed to
cool at room temperature. Samples alkylation was carried out at room temperature by
adding 100 mM of iodoacetamide (IAA) and the vials were incubated in the dark for 15 mins.
Deionized water was added followed by the addition of 2μg trypsin. After adding trypsin
samples were digested on a thermomixer (Eppendorf, Germany) for 16 hours at 600 rpm and
37°C. The digestion process was stopped by adding 2% TFA (60μL, pH ≤3). All digests were
stored at -20°C.

Mass spectrometry analysis

Peptide digests were analyzed by nano- LC-MS/MS system on a Q Exactive HF
Orbitrap LC-MS/MS system (Thermo Fischer) coupled to an EASY-LC 1000 system (Thermo
Fischer Scientific). Long-fused silica capillary column (PicoFirt 18 cm, 75 m inner diameter)
was packed in-house with reversed-phase Repro-SilPur C18-AQ 3 m resin and used to load
1mg of purified peptides. Peptides were eluted from Buffer A (0.1% Formic acid) at a flow
rate of 250 nL/min followed by elusion through buffer B (95% acetonitrile in 0.1% Formic
acid). The gradient gradually increased in B from 5% to 28% in 40 mins, 45% in 60 mins, and

finally to 100% in the end. The Q-Exactive HF was set up to operate in data-dependent
acquisition mode with the following parameters: full scan automatic gain control (AGC)
target 3e6 at 120000 FWHM resolution, scan range 350-1600 mz, Orbitrap full scan
maximum injection time 100 ms, normalized collision energy 28, a dynamic exclusion time of
the 30s, an isolation window of 1.2 m/z and top 20 MS2 scans per MS full scan.

Statistical data analysis

The statistical analysis of the data was performed by importing protein groups from
MaxQuant. The analysis was carried out on Perseus v.1.6.10.50 after removing potential
contaminants, reverse database hits, and protein identified by site, log2 transformation was
carried out. The samples were categorized into four groups (DEN-treated female mice, DEN-
treated male mice, Vehicle-treated male mice, and vehicle-treated female mice). Proteins
were further filtered to include only those with at least three valid values in each group.
Significance testing of protein LFQ intensities was carried out by post hoc Tukey's HSD test
for one-way ANOVA with a p-value threshold of <0.05 (Benjamini-Hochberg FDR at 0.05)
considered significant. Groupwise comparisons were carried out using a functional analysis
tool. Principal component analysis was carried out to see the differentiation of treated and
control samples. Heat maps were generated using Perseus v.1.6.10.50, displaying protein
intensities with non-supervised hierarchical clustering of rows. Volcano plots were made to
represent differentially expressed proteins.

Gene enrichment analysis

The biological significance of the differentially expressed proteins was determined
through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG)
enrichment analysis (https://www.kegg.jp/kegg/pathway.html, p adj value < 0.05),
Reactome analysis (https://reactome.org/Pathway.html, p adj value < 0.05) that identifies
pathways enriched in the proteins of interest and through Gene ontology enrichment
analysis to determine whether GO terms about specific processes, molecular functions, or
cellular components are represented within the DEP set. Overrepresentation analysis of GO,
KEGG, and Reactome terms was performed using the R package (clusterprofiler).

PPI and hub proteins

172 Functional associations or physical interactions between proteins network was
173 visualized using the STRING database and Cytoscape. The significant module for each
174 network was obtained by MCODE using default parameters. Moreover, the MCC method was
175 used to select hub genes from the PPI network using the CytoHubba plugin of Cytoscape.

Survival analysis

177 The clinical value of differentially expressed proteins was estimated by converting 20
178 hub proteins to their human homologs using the "biomaRt" R package. Protein expression of

179 human homologous proteins corresponding to DEPs was matched with overall survival using
180 the UALCAN tool.

Results

DEN-Induced Mouse Model for Male and Female HCC

DEN-induced HCC mouse model for male and female Balb/c mice was constructed
following one of the methods described by Peng et al. (2024) with some modifications.
Consistent with the gender bias in HCC all six female mice in the treatment group survived
until 8 months whereas only 2 male mice survived till the end. Subsequent analysis was
performed with the surviving individuals of the groups. Normal and tumor tissues with
internal and external controls were collected from control and treated mice of both genders
separately for the histological and proteomic analysis (**Fig. 1A**). In the DEN-induced mouse
model multiple tumors developed in the liver. H&E staining revealed that hepatocytes in the
liver of control mice were neatly arranged with normal cellular morphology. In contrast,
hepatocytes in the tumor tissue showed disorganized morphology, large nuclei, and immune
infiltration suggesting DEN-induced carcinogenesis in the mouse liver (**Fig. 1B**).
Immunohistochemical analysis showed that positive cells for E-Cadherin were greater in
vehicle-treated mice compared to the DEN-treated mice which suggest loss of cellular
adhesion and increased proliferation and migration (**Fig. 2A**). The positive area for vimentin
were significantly increased in tumor tissue compared with normal tissues (**Figs. 2B and 2C**).
These results indicated that the DEN-induced mouse model was successfully constructed
with characteristic proliferative features.

Figure 1. A, Schematic diagram of the development of DEN-induced HCC in Balb/c mice B, H&E staining of mouse liver indicating the development of HCC in DEN-treated male and female mice. Half circular arrows indicate enlarged nuclei, arrows indicate immune infiltration and arrow heads show disorganized morphology.

Figure 2. Immunohistochemical (IHC) staining of liver sections from vehicle-treated and DEN-
treated mice. **A,** E-Cadherin staining of vehicle-treated, and DEN-treated male/female mice
B, Vimentin staining of vehicle-treated and DEN-treated male/female mice.

Statistical data analysis

In the present study, protein samples isolated from 14 mice were analyzed through
label-free LC-MS which led to the identification of total 2897 proteins (Supplementary Table
1). After the filtration of potential contaminants, only identified by site and reverse database
hits 2803 proteins were selected and divided into four groups (Treated Male Mice, Treated
Female Mice, Control Male Mice, and Control Female Mice). From this point onwards, data
was segregated gender wise followed by separate Log2 transformation of both male and
female LFQ intensities of proteins. Both groups were separately subjected to filtration based
on 70% values in each group, reducing the total number of proteins to 1419 and 1049 in
males and females respectively. After filtration post hoc Tukey's HSD test for one-way
ANOVA was used to test the significance of the expressed protein based on the difference
between the LFQ intensities of treatment and control groups. In female mice, 857 proteins
were found to be common between treatment and control groups whereas 192 proteins
were significantly differentially expressed among which 54 proteins were downregulated
(Supplementary Table 2) and 138 proteins were upregulated (Supplementary Table 3). In
male mice, 1273 proteins were found to be common between treatment and control groups
whereas 146 proteins were found to be significantly differentially expressed among which 61
proteins were upregulated (Supplementary Table 4) whereas 85 proteins were
downregulated (Supplementary Table 4). Supplementary Tables 2,3,4 and 5 display the
protein IDs, gene names, and unique peptides of the altered proteins in the treatment
groups of male and female mice.

Venn diagrams of gender-wise comparisons indicated that among the upregulated
proteins 8 proteins were common between both male and female mice whereas 53 and 130
were differentially expressed between male and female mice respectively. Among the
downregulated proteins, 2 proteins were common between the male and female mice
whereas 83 and 52 proteins were differentially expressed between male and female mice
respectively (**Fig. 3 A-C**).

Figure 3. A, Among the significantly downregulated proteins only 1 protein (Indolethylamine
N-methyltransferase) was common in both male and female mice. **B,** Among the significantly

upregulated proteins 9 proteins, (Tropomyosin 3, related sequence 7, Nucleolin, Histone
H1.2, Tropomyosin alpha-3 chain, Lamina-associated polypeptide 2, Heterogeneous nuclear
ribonucleoprotein U, Heterogeneous nuclear ribonucleoprotein M, ES1 protein homolog,
mitochondrial were common in both male and Female mice. **C,** Combined representation of
common and differentially expressed proteins in treated male and female mice.

Heat maps represent hierarchical clustering and comparison between different
samples in both male and female sets (**Fig. 4 A, B**). Principal component analysis (PCA) was
carried out to obtain the major features of the data. Control and treated groups were clearly
separated on the PCA plot for female mice with 55.3% contribution from component 1 and
15.3% contribution from component 2 (**Fig. 5A**). For the male mice the separation was wider
with the control group aligned on the right and treated group aligned on the left vertically,
component 1 making 96.9 % contribution while component 2 made 2.3 % contribution (**Fig.**
5B). Volcano plots for male and female sets represent the relationship between FDR and fold
change (p-value $\leq$ 0.05, |log2FC| $\geq$ 0.5) (**Fig. 5 C, D**).

255
256

Figure 4. Heatmap of DEPs expression in non-tumor and tumor tissues of **A,** male and **B,**
female groups. Perseus software (version 2.0.11.01`1) was used to create a heat map.

A

C

D

Figure 5. PCA Plots represent the separation between the two components in female **A,**
male **B,** groups. The blue color indicates the control group whereas the red color indicates
the treatment group. Volcano plot of differentially expressed proteins in female **C,** and male
D, sets. Brown dots represent down-regulated proteins, black dots represent up-regulated
proteins and grey dots represent proteins with insignificant differences.

Enrichment of cytoskeletal, mitochondrial, metabolic and Oxidoreductase Clusters in
Females

Functional enrichment analysis (Gene Ontology (GO)), Reactome Analysis, and KEGG
pathway analysis) of DEPs was performed to study the biological relevance of significantly
altered proteins. First, GO analysis was performed in terms of biological processes (BP),
cellular composition (CC), and molecular function (MF) (**Fig. 6 A, B**). The up-regulated
proteins in treated female mice were mainly involved in structural constituent of
cytoskeleton, protein folding, purine nucleoside triphosphate metabolic process and
structural and functional constituents of mitochondria whereas, the downregulated proteins
were largely concerned various metabolic and catabolic processes and oxidoreductase
activity (**Fig. 6A**).Reactome pathway overrepresentation analysis further revealed that
proteins involved in the metabolism of (RNA and protein), caspase-mediated cleavage of
cytoskeletal proteins were upregulated in female mice (**Fig. 6C**). Finally, KEGG pathway
analysis showed that proteins involved in chemical carcinogenesis and formation of reactive

oxygen species, oxidative phosphorylation, nonalcoholic fatty liver disease was upregulated
in treated female mice and downregulated in treated male mice whereas proteins involved
in Tryptophan metabolism were downregulated in treated female mice and upregulated in
treated male mice. Proteins involved in chemical carcinogenesis-DNA adduct, and
glutathione metabolism were downregulated in treated male mice whereas genes related to
ribosomes, Taurine, hypotaurine metabolism, Pantothenate, and CoA biosynthesis were
upregulated in treated male mice. In treated female mice proteins involved in Retinol
metabolism, Pyruvate metabolism, Fatty acid degradation, Cysteine and methionine
metabolism, Fatty acid metabolism and biosynthesis, Glycolysis / Gluconeogenesis Drug
metabolism, cytochrome P450, Alcoholic liver disease were downregulated whereas
proteins involved in PARP signaling pathway, cytoskeleton in muscle cells were upregulated.
Only one pathway of carbon metabolism was downregulated in both treated male and
female mice (**Fig. 6D**).

Enrichment of translational, Ribosomal and Mitochondrial Clusters in Male Mice

The upregulated proteins in treated male mice were related to translation, ribosomal
structural and binding subunits and mRNA binding, whereas the downregulated proteins
were predominantly related to generation of precursor metabolites, metabolic processes,
catabolic processes, glutathione transferase activity, oxidoreductase activity and
mitochondrial activity (**Fig. 6B**). Reactome pathway overrepresentation analysis further
revealed that in male mice proteins associated with ribosomal processing, translation
initiation, dependent and independent nonsense mediated decay, apoptosis and apoptosis
induced DNA fragmentation were upregulated whereas proteins involved in fatty acid
metabolism, respiratory electron transport chain, cellular response to chemical stress,
metabolism of amino acid and derivatives, TP53 regulated metabolic genes, degradation of
beta catenin by the destruction complex, apoptotic execution phase, signaling by Rho
GTPase, ribosomal scanning and start codon recognition, citric acid cycle, and respiratory
electron transport chain were downregulated in treated male mice.

A

B

C

313
314 **D**

316 **Figure 6.** Overrepresentation Analysis **A,** GO term Analysis of female mice **B,** GO term
317 analysis of male mice **C,** Reactome Analysis of DEN-treated male and female mice **D,** KEG
318 pathway Analysis of DEN-treated male and female mice.

PPI networks in Male and Female mice

For DEPs in male and female mice, the PPI network was constructed using the STRING database and Cytoscape. The male PPI network consisted of 108 nodes with 922 edges while the female PPI network contained 217 nodes with 2042 edges (**Fig. 7 A, B**). The significant module for each network was obtained by MCODE using default parameters. MCODE score of the top modules was 13.538 (male) and 14.571 (female) (**Fig. 8 A, B**). Moreover, the MCC method was used to select hub genes from the PPI network using the CytoHubba plugin of Cytoscape. In the male cluster top ten genes ranked by highest maximal clique centrality (MCC) were Rpl13, Rpl4, Eef2, Rps11, Rpl18a, Serbp1, Rpl27a, Rpl3, Rpl7a and Rps3. These were identified as hub genes for the male network (**Fig. 9A**). For the female cluster Hub genes were identified to be Uqcrb, Cox6b1, Ndufc2, Ndufa8, Sdhb, Atp5d, Ndufa7, Ndufa2 and Ndufs6 (**Fig. 9B**). Over representation analysis of hub genes is indicated in **Figure 9C.**

 A

337   **B**

Figure 7. A, STRING analysis of DEN-treated female mice **B,** STRING analysis of DEN-treated male mice.

A

B

Figure 8. Pathway interaction using Cytoscape **A,** Pathway interaction in DEN-treated female
mice **B,** pathway interaction in DEN-treated Male Mice.

A

C

Figure 9. A, Hub gene analysis of DEN-treated female mice, **B,** Hub gene analysis of DEN-treated male mice **C,** ORA of hub genes in both DEN-treated male and female mice.

Prognostic value of RNA Binding and Ribosomal Proteins in Male Mice and mitochondrial Protein NDUFA8 in Female mice

To identify the relationship between expression of Hub protein and overall survival time of patients and to evaluate prognostic value of Hub proteins, survival analysis of human homologs of all Hub genes was carried out using online tool UCLAN. The results indicated

that six hub genes were significantly associated with overall poor patient survival. Among
the hub genes of DEN-treated female mice only the upregulation of NDUFA8 ($P < 0.017$) was
associated with poor patient survival (**Fig. 10A**). In DEN-treated male mice downregulation
of EEF2 ($P < 0.022$) and upregulation of RPL7A ($P < 0.0031$), RPL18A ($P < 0.003$), RPL27A ($P <$
0.023), RPS3 ($P < 0.016$), RPS 11 ($P < 0.004$) and SERBP1 ($P < 0.0029$) was associated with
poor patient survival (**Fig. 10 B-H**).

A

B

C

D

E

F

G

H

Figure 10. Survival Analysis of Hub genes. Survival Curve of **A,** EEF2 **B,** NDUFA8 **C,** RPL7A **D,**
RPL 18A **E,** RPL27A **F,** RPS3 **G,** RPS11 **H,** SERBP1.

Discussion

Hepatocellular carcinoma (HCC) is a heterogeneous disease influenced by various factors, including its multi-stage progression and a male-to-female incidence ratio of 4:1 (Park et al., 2015), making it a leading cause of mortality among men worldwide. Given this complexity, using a single-gender animal model for HCC research is insufficient. This study aims to provide gender-specific proteomic data from DEN-induced HCC mouse models to better understand the distinct molecular mechanisms driving HCC's etiology, prevalence, and pathogenesis in males and females, and to identify gender-specific biomarkers and treatment strategies. While proteomic studies of HCC are common, comparative analyses between genders are rare. Recent findings suggest male rodents show greater susceptibility to hepatocarcinogenesis, indicating that gender-related molecular mechanisms contribute to HCC prevalence in males. However, the underlying reasons for gender disparities in HCC incidence, survival, and prognosis remain unclear.

Rong et al. (2017) reported that not only do gender-dependent biological processes occur in hepatic tumorigenesis but also gender-dependent molecular responses to oncogenes occur in normal hepatocytes. The study showed that in male mice pathways associated with signal transduction, transport, and metabolism were upregulated while females exhibited mostly downregulated metabolic and antioxidant proteins. Consistent with this, our study showed that DEN-treated female mice represent upregulated catabolic and metabolic pathways whereas pathways for fatty acid, sulfur compound, acyl-CoA, thioester, and ribonucleotide metabolism were downregulated in DEN-treated female mice. In addition to affirming the findings of Rong et al. (2017), the present study also indicates that pathways associated with metabolic and catabolic processes were downregulated in DEN-treated male mice as opposed to the case of female mice whereas pathways associated with translation, mRNA binding, ribosome structure and binding were upregulated in male mice.

Zhang et al (2024) reported in their study that DEN and CCl4-induced HCC mouse models show significant upregulation of the actin cytoskeleton which is linked to the activation of hepatic stellate cells (HSCs), which contributes to liver injury and collagen-rich extracellular matrix formation. Consistent with these findings we observed enrichment of pathways associated with structural constituent of cytoskeleton and cortical cytoskeleton, particularly pathways associated with actin filament and binding. This alteration in the actin cytoskeleton is crucial in cancer processes, suggesting it as a potential therapeutic target for HCC in females.

DEN-treated male mice clearly showed distinct expression patterns compared to their female counterparts. Most of the hub proteins obtained from PPI networks belonged to either RNA binding proteins or ribosomal proteins indicating post-transcriptional modifications in expression. Ribosomal proteins (RPs) are a family of canonical RBPs. In addition to playing central roles in ribosome biogenesis and protein synthesis, RPs are also

found to be involved in cell proliferation, apoptosis, invasion, and metastasis via a number of
mechanisms including transcription regulation, autophagy, phosphorylation and RNA-
binding function (Warner and McIntosh, 2009; Ebright et al., 2020; Pecoraro et al., 2021;
Ceci et al., 2021), and therefore participate in the occurrence and development of multiple
cancers types including HCC (Zhou et al., 2024; Zhang et al., 2022). Nevertheless, to date,
only a few HCC-related RBPs have been well characterized. In our study RBPs have been
found to be extensively differentially enriched across genders. Hub gene analysis of DEN-
induced HCC in male mice shows that Rpl4, Rpl7a, Rpl27a, Rps29, Rps3, Rpl3, Rpl13, Rpl18a,
and Rps11 were upregulated in DEN-treated male mice whereas Hub gene analysis of DEN-
treated female mice didn't show enrichment of ribosomal pathways. To our knowledge this
is the first report of DEN-induced, gender-biased, perturbations in ribosomal proteins.
However, these results need to be further validated through Western blot analysis.

RPS3 has been frequently reported to be upregulated in human HCC and is found to
be associated with aggressiveness and promotion of hepatocarcinogenesis. Knockdown of
RPS3 has been found to almost completely abolish HCC tumorigenesis both in vitro and in
vivo (Schäfer et al., 2006). Consistent with the previous reports, we also reported the
upregulation of RPS3 and its association with poor survival outcomes in DEN-treated male
mice. RPL3 also plays a ubiquitous role in regulating tumor phenotypes, many clusters of
tumors with down-regulated RPL3, including HCC, kidney clear cell cancer, and brain cancer,
possessed inferior survival (Dolezal et al., 2018). The present study showed that RPL3 was
significantly upregulated in hub gene analysis, but it was not found to be significantly
associated with survival outcomes. Overexpression of RPS 11 is associated with poor
prognosis in glioblastoma (Yong et al., 2015). We have also reported that the upregulation of
RPS 11 in the DEN-induced HCC model of male mice is associated with poor survival. The
role of RPS 11 has not yet been established clearly in human hepatocellular carcinoma,
hence this study makes RPS 11 a potential candidate for evaluating its potential as a
prognostic marker and a therapeutic target. This study also reports the upregulation of
RPL13 in Hub gene analysis of DEN-treated male mice which has been correlated with
gastrointestinal malignancies (Kobayashi et al., 2006) but has not yet been reported in liver
cancer so far. Immunohistochemical staining of eEF2 and peEF2(T56) showed that this
protein and its phosphorylation are highly significant prognostic markers for the overall
survival of HCC patients (Pott et al., 2017) which has been consistently replicated in the
survival analysis of DEN-treated male mice, in this study.

The Ndufc2, Ndufv3, Ndufa8, Ndufa7, Ndufa2, and Ndufs6 hub genes in DEN-treated
female mice belonged to the NADH dehydrogenase (ubiquinone) oxidoreductase complex.
These hub genes are six out of at least 41 subunits of mitochondrial respiratory chain
complex 1 which is the 1st and largest enzyme complex of the electron transport chain.
Ndufa8 is the only protein in DEN-treated female mice that showed an association with
patient survival. Higher levels of Ndufa8 were associated with poor survival. It has not been
previously reported to be involved in liver cancer. Liver cells are highly regenerative and

require high energy hence a higher number of mitochondria. Abnormalities in mitochondrial
metabolism are known to be carcinogenic factors (Jin et al., 2020). The role of complex 1
subunits in liver cancer has scarcely been studied so far, hence our findings open new vistas
of research for exploring female HCC in the context of mitochondrial metabolic disease.

This study was conducted with a limited number of experimental animals. Notably, the early
loss of three male mice reduced the sample size in that group; however, this observation
aligns with previously reported gender-based differences in survival, where male subjects
exhibit poorer outcomes in hepatocellular carcinoma (HCC) models compared to females.
Our survival analysis supports this trend, as five proteins were associated with the male
cohort, whereas only one protein showed significant association in females. Although direct
experimental validation of several novel proteins identified through bioinformatics
approaches (e.g., via Western blotting or immunohistochemistry) was not feasible due to
resource constraints, the proteomic findings remained internally consistent and were further
substantiated through literature-based validation.

Conclusion

We concluded that DEN-induced male and female mouse models for hepatocellular
carcinoma exhibit distinct molecular signatures, thereby following different pathological and
prognostic courses in clinical settings. The divergent groups of proteins associated with poor
survival—ribosomal (RPS3, RPS 11) and RNA binding proteins (RPL7A, RPL 18A, RPL27A) in
males, and mitochondrial complex I protein (NDUFA8) in females—can be further
investigated as potential gender-specific prognostic markers and therapeutic targets.
Developing gender-specific therapeutic regimens may open new prospects in the
management of liver cancer, particularly in HCC.

Ethics Approval and Consent to Participate

478 All animal protocols were in accordance with ARRIVE guidelines and were approved by the
479 ethical committee for research of International Islamic University Islamabad, Pakistan. The
480 methods of this study were informed to all the authors and were conducted in accordance
481 with relevant guidelines and regulations.

Data Availability Statement

483 Data is provided within the manuscript or supplementary files

Acknowledgments

We are grateful to the Pakistan Science Foundation for partially funding this research via PSF
grant# 733. We are thankful to Molecular Oncology Research Lab for serving as a base camp
for this project. We also appreciate Dr. Ikramullah for allowing us to use the animal house
facility at the Center for Interdisciplinary Research in Basic Science (CIRBS), International
Islamic University Islamabad. The study was supported by the VILLUM Center for Bio

analytical Sciences at University of Southern Denmark and by PRO-MS, Danish National
Mass Spectrometry Platform for Functional Proteomics.

References

1. Bastide A, & David, A. (2018). The ribosome, (slow) beating heart of cancer (stem)
cell. Oncogenesis, 7(4), 34. https://doi.org/10.1038/s41389-018-0044-8

2. Ceci, M., Fazi, F., & Romano, N. (2021). The role of RNA-binding and ribosomal
proteins as specific RNA translation regulators in cellular differentiation and
carcinogenesis. Biocchimica et biophysica acta. Molecular basis of disease, 1867(4),
166046. https://doi.org/10.1016/j.bbadis.2020.166046

3. Corley, M., Burns, M. C., & Yeo, G. W. (2020). How RNA-Binding Proteins Interact with
RNA: Molecules and Mechanisms. Molecular cell, 78(1), 9–29. https://doi.org/10
https://doi.org/10.1016/j.bbamcr.2008.10.017

4. Kim, Y., Kim, H. D., & Kim, J. (2013). Cytoplasmic ribosomal protein S3 (rpS3) plays a
pivotal role in mitochondrial DNA damage surveillance. Biochimica et biophysica
acta, 1833(12), 2943–2952. https://doi.org/10.1016/j.bbamcr.2013.07.015

5. Kobayashi, T., Sasaki, Y., Oshima, Y., Yamamoto, H., Mita, H., Suzuki, H., Toyota, M.,
Tokino, T., Itoh, F., Imai, K., & Shinomura, Y. (2006). Activation of the ribosomal
protein L13 gene in human gastrointestinal cancer. International journal of molecular
medicine, 18(1), 161–170.

6. Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D.,
Meeteren, N. S., Caron, H. N., Cloos, J., Mrsić, A., Ylstra, B., Grajkowska, W.,
Hartmann, W., Pietsch, T., Ellison, D., Clifford, S. C., & Versteeg, R. (2008). Integrated
genomics identifies five medulloblastoma subtypes with distinct genetic profiles,
pathway signatures and clinicopathological features. PloS one, 3(8), e3088.
https://doi.org/10.1371/journal.pone.0003088

7. Liu, S., Li, B., Liang, Q., Liu, A., Qu, L., & Yang, J. (2020). Classification and function of
RNA-protein interactions. Wiley interdisciplinary reviews. RNA, 11(6), e1601.
https://doi.org/10.1002/wrna.1601

8. Pecoraro, A., Pagano, M., Russo, G., & Russo, A. (2021). Ribosome Biogenesis and
Cancer: Overview on Ribosomal Proteins. International journal of molecular sciences,
22(11), 5496. https://doi.org/10.3390/ijms22115496

9. Pott, L. L., Hagemann, S., Reis, H., Lorenz, K., Bracht, T., Herold, T., Skryabin, B. V.,
Megger, D. A., Kälsch, J., Weber, F., Sitek, B., & Baba, H. A. (2017). Eukaryotic
elongation factor 2 is a prognostic marker and its kinase a potential therapeutic
target in HCC. Oncotarget, 8(7), 11950–11962.
https://doi.org/10.18632/oncotarget.14447

10. Rong, Z., Fan, T., Li, H., Li, J., Wang, K., Wang, X., Dong, J., Chen, J., Wang, F., Wang, J.,
& Wang, A. (2017). Differential Proteomic Analysis of Gender-dependent Hepatic
Tumorigenesis in Hras12V Transgenic Mice. Molecular & cellular proteomics: MCP,
16(8), 1475–1490. https://doi.org/10.1074/mcp.M116.065474

11. Russo, A., Saide, A., Cagliani, R., Cantile, M., Botti, G., & Russo, G. (2016). rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFκB upon 5-FU treatment. Scientific reports, 6, 38369. https://doi.org/10.1038/srep38369

12. Russo, A., Saide, A., Smaldone, S., Faraonio, R., & Russo, G. (2017). Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells. International journal of molecular sciences, 18(3), 547. https://doi.org/10.3390/ijms18030547

13. Schäfer, T., Maco, B., Petfalski, E., Tollervey, D., Böttcher, B., Aebi, U., & Hurt, E. (2006). Hrr25-dependent phosphorylation state regulates organization of the pre-40S subunit. Nature, 441(7093), 651–655. https://doi.org/10.1038/nature04840

14. Warner, J. R., & McIntosh, K. B. (2009). How common are extraribosomal functions of ribosomal proteins?. Molecular cell, 34(1), 3–11. https://doi.org/10.1016/j.molcel.2009.03.006

15. Wier, E. M., Neighoff, J., Sun, X., Fu, K., & Wan, F. (2012). Identification of an N-terminal truncation of the NF-κB p65 subunit that specifically modulates ribosomal protein S3-dependent NF-κB gene expression. The Journal of biological chemistry, 287(51), 43019–43029. https://doi.org/10.1074/jbc.M112.388694

16. Wu, Y., Meng, X., Huang, C., & Li, J. (2015). Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36(6), 4063–4074. https://doi.org/10.1007/s13277-015-3488-x

17. Yadavilli, S., Mayo, L. D., Higgins, M., Lain, S., Hegde, V., & Deutsch, W. A. (2009). Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA repair, 8(10), 1215–1224. https://doi.org/10.1016/j.dnarep.2009.07.003

18. Yong, W. H., Shabihkhani, M., Telesca, D., Yang, S., Tso, J. L., Menjivar, J. C., Wei, B., Lucey, G. M., Mareninov, S., Chen, Z., Liau, L. M., Lai, A., Nelson, S. F., Cloughesy, T. F., & Tso, C. L. (2015). Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PloS one, 10(10), e0141334. https://doi.org/10.1371/journal.pone.0141334

19. Zhang, K., Barry, A. E., Lamm, R., Patel, K., Schafer, M., & Dang, H. (2022). The role of RNA binding proteins in hepatocellular carcinoma. Advanced drug delivery reviews, 182, 114114. https://doi.org/10.1016/j.addr.2022.114114

20. Zhang, Q., Liu, Y., Ren, L., Li, J., Lin, W., Lou, L., Wang, M., Li, C., & Jiang, Y. (2024). Proteomic analysis of DEN and CCl4-induced hepatocellular carcinoma mouse model. Scientific Reports, 14(1), 8013. https://doi.org/10.1038/s41598-024-58587-6

21. Zhou, X., Liao, W. J., Liao, J. M., Liao, P., & Lu, H. (2015). Ribosomal proteins: functions beyond the ribosome. Journal of molecular cell biology, 7(2), 92–104. https://doi.org/10.1093/jmcb/mjv014

571   22. Zhou, Y. J., Yang, M. L., He, X., Gu, H. Y., Ren, J. H., Cheng, S. T., Fu, Z., Zhang, Z. Z., &
572   Chen, J. (2024). RNA-binding protein RPS7 promotes hepatocellular carcinoma
573   progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling. Journal of
574   experimental & clinical cancer research: CR, 43(1), 45.
575   https://doi.org/10.1186/s13046-023-02929-1

Table 1: List of Significantly Downregulated Proteins in Treated Female Mice

Protein IDs	Protein names	Unique peptides	Gene names
P62702	40S ribosomal protein S4, X isoform	16	Rps4x
Q9CRB3	5-hydroxyisourate hydrolase	9	Urah
Q9D1R9	60S ribosomal protein L34	8	Rpl34
Q8VCW8	Acyl-CoA synthetase family member 2, mitochondrial	31	Acsf2
Q8BGQ7	Alanine--tRNA ligase, cytoplasmic	33	Aars
P00329	Alcohol dehydrogenase 1	32	Adh1
Q8VC28	Aldo-keto reductase family 1 member C13	3	Akr1c13
P17182	Alpha-enolase	50	Eno1
B1AU25	Apoptosis-inducing factor 1, mitochondrial	27	Aifm1
Q3V117	ATP-citrate synthase	65	Acly
Q8CGC7	Bifunctional glutamate/proline--tRNA ligase;Glutamate--tRNA ligase;Proline--tRNA ligase	37	Eprs
Q8C196	Carbamoyl-phosphate synthase [ammonia], mitochondrial	177	Cps1
Q8VCT4	Carboxylesterase 1D	37	Ces1d
Q9CZU6	Citrate synthase, mitochondrial;Citrate synthase	22	Cs
P01027	Complement C3;Complement C3 beta chain;C3-beta-c;Complement C3 alpha chain;C3a anaphylatoxin;Acylation stimulating protein;Complement C3b alpha chain;Complement C3c alpha chain fragment 1;Complement C3dg fragment;Complement C3g fragment;Complement C3d fragment;Complement C3f fragment;Complement C3c alpha chain fragment 2	65	C3
P01029	Complement C4-B;Complement C4 beta chain;Complement C4 alpha chain;C4a anaphylatoxin;Complement C4 gamma chain	25	C4b
P00405	Cytochrome c oxidase subunit 2	6	Mtco2
P00186	Cytochrome P450 1A2	17	Cyp1a2
P15392	Cytochrome P450 2A4	9	Cyp2a4
P28271	Cytoplasmic aconitate hydratase	47	Aco1
Q99L04	Dehydrogenase/reductase SDR family member 1	18	Dhrs1
Q9D2G2	Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial	19	Dlst
P50285	Dimethylaniline monooxygenase [N-oxide-forming] 1	19	Fmo1
Q8JZQ9	Eukaryotic translation initiation factor 3 subunit B	13	Eif3b
P19096	Fatty acid synthase;[Acyl-carrier-protein] S-	126	Fasn

	acetyltransferase;[Acyl-carrier-protein] S-malonyltransferase;3-oxoacyl-[acyl-carrier-protein] synthase;3-oxoacyl-[acyl-carrier-protein] reductase;3-hydroxyacyl-[acyl-carrier-protein] dehydratase;Enoyl-[acyl-carrier-protein] reductase;Oleoyl-[acyl-carrier-protein] hydrolase		
Q3UER8	Fibrinogen gamma chain	16	Fgg
A0A0A0MQF6	Glyceraldehyde-3-phosphate dehydrogenase	29	Gapdh
B1ASZ3	Glycerol kinase	13	Gyk;Gk
O35969	Guanidinoacetate N-methyltransferase	6	Gamt
P54869	Hydroxymethylglutaryl-CoA synthase, mitochondrial	41	Hmgcs2
P40936	Indolethylamine N-methyltransferase	18	Inmt
Q61703	Inter-alpha-trypsin inhibitor heavy chain H2	6	Itih2
Q9CXF0	Kynureninase	14	Kynu
P06151	L-lactate dehydrogenase A chain;L-lactate dehydrogenase	30	Ldha
Q8JZR0	Long-chain-fatty-acid--CoA ligase 5	21	Acsl5
A0A1Y7VJZ2	Maleylacetoacetate isomerase	15	Gstz1
O08601	Microsomal triglyceride transfer protein large subunit	34	Mttp
Q91X91	Nicotinate-nucleotide pyrophosphorylase [carboxylating]	10	Qprt
E9PZF0	Nucleoside diphosphate kinase;Nucleoside diphosphate kinase B	7	Gm20390
P24369	Peptidyl-prolyl cis-trans isomerase B	19	Ppib
P35700	Peroxiredoxin-1	31	Prdx1
Q9QXD1	Peroxisomal acyl-coenzyme A oxidase 2	27	Acox2
Q9DBM2	Peroxisomal bifunctional enzyme;Enoyl-CoA hydratase/3,2-trans-enoyl-CoA isomerase;3-hydroxyacyl-CoA dehydrogenase	52	Ehhadh
Q60866	Phosphotriesterase-related protein	16	Pter
P20918	Plasminogen;Plasmin heavy chain A;Activation peptide;Angiostatin;Plasmin heavy chain A, short form;Plasmin light chain B	24	Plg
Q9DCQ2	Putative L-aspartate dehydrogenase	17	Aspdh
P61027	Ras-related protein Rab-10	3	Rab10
P62821	Ras-related protein Rab-1A	6	Rab1A
O88451	Retinol dehydrogenase 7	13	Rdh7
Q9R0P3	S-formylglutathione hydrolase	12	Esd
P80316	T-complex protein 1 subunit epsilon	17	Cct5
Q9D0R2	Threonine--tRNA ligase, cytoplasmic	25	Tars
P61089	Ubiquitin-conjugating enzyme E2 N	8	Ube2n
Q3UEL5	Urocanate hydratase	33	Uroc1

Table 2: List of Significantly Upregulated Proteins in Treated Female Mice

Protein IDs	Protein names	Unique peptides	Gene names
Q99JT9	1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase	11	Adi1
Q64433	10 kDa heat shock protein, mitochondrial	29	Hspe1
P68510	14-3-3 protein eta	8	Ywhah
P58871	182 kDa tankyrase-1-binding protein	20	Tnks1bp1
Q9CQX8	28S ribosomal protein S36, mitochondrial	4	Mrps36
Q283N4	2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase	15	Urad
P62858	40S ribosomal protein S28	14	Rps28
L7N466	5-formyltetrahydrofolate cyclo-ligase	1	Mthfsl
P63038	60 kDa heat shock protein, mitochondrial	86	Hspd1
Q9EST5	Acidic leucine-rich nuclear phosphoprotein 32 family member B	7	Anp32b
Q99JY9	Actin-related protein 3	21	Actr3
P55264	Adenosine kinase	13	Adk
P46656	Adrenodoxin	10	Fdx1
P57780	Alpha-actinin-4	42	Actn4
P09813	Apolipoprotein A-II	5	Apoa2
Q9D3D9	ATP synthase subunit delta	7	Atp5d
P56382	ATP synthase subunit epsilon	9	Atp5e
P97450	ATP synthase-coupling factor 6	13	Atp5j
E9PV44	ATPase inhibitor, mitochondrial	15	Atpif1
E9PZ16	Basement membrane-specific heparan sulfate proteoglycan core protein	29	Hspg2
P26231	Catenin alpha-1	19	Ctnna1
Q61490	CD166 antigen	13	Alcam
D3YVV1	Cell cycle control protein 50A	7	Tmem30a
P23198	Chromobox protein homolog 3	8	Cbx3
P45591	Cofilin-2	9	Cfl2
Q8R3Q6	Coiled-coil domain-containing protein 58	12	Ccdc58
Q9WUM4	Coronin-1C	12	Coro1c
Q9CPZ8	COX assembly mitochondrial protein homolog	4	Cmc1
Q9DCT8	Cysteine-rich protein 2	10	Crip2
P56395	Cytochrome b5	20	Cyb5a
Q9D855	Cytochrome b-c1 complex subunit 7	19	Uqcrb
Q8BGD8	Cytochrome c oxidase assembly factor 6 homolog	3	Coa6
Q921H9	Cytochrome c oxidase assembly factor 7	9	Coa7

P56391	Cytochrome c oxidase subunit 6B1	14	Cox6b1
O88487	Cytoplasmic dynein 1 intermediate chain 2	7	Dync1i2
Q91XC8	Death-associated protein 1	9	Dap
P97821	Dipeptidyl peptidase 1 exclusion domain chain	5	Ctsc
A2A5S3	Double-stranded RNA-binding protein Staufen homolog 1	8	Stau1
Q62418	Drebrin-like protein	15	Dbnl
O70251	Elongation factor 1-beta	20	Eef1b
Q9D172	ES1 protein homolog, mitochondrial	24	D10Jhu81e
Q9Z1D1	Eukaryotic translation initiation factor 3 subunit G	11	Eif3g
Q8BGD9	Eukaryotic translation initiation factor 4B	30	Eif4b
P59325	Eukaryotic translation initiation factor 5	15	Eif5
Q3U0V1	Far upstream element-binding protein 2	24	Khsrp
P09528	Ferritin heavy chain	20	Fth1
P29391	Ferritin light chain 1	6	Ftl1
A0A494BAI5	Ferrochelatase	10	Fech
Q3U9N4	Granulins	16	Grn
Q99LP6	GrpE protein homolog 1	20	Grpel1
Q9R257	Heme-binding protein 1	14	Hebp1
Q5EBP8	Heterogeneous nuclear ribonucleoprotein	11	Hnrnpa1
Q60668	Heterogeneous nuclear ribonucleoprotein D0	16	Hnrnpd
B2M1R6	Heterogeneous nuclear ribonucleoprotein K	32	Hnrnpk
Q9D0E1	Heterogeneous nuclear ribonucleoprotein M	40	Hnrnpm
Q8VEK3	Heterogeneous nuclear ribonucleoprotein U	27	Hnrnpu
Q9Z204	Heterogeneous nuclear ribonucleoproteins C1/C2	19	Hnrnpc
A0A0J9YUZ4	High mobility group protein B1	21	Hmgb1
P17095	High mobility group protein HMG-I/HMG-Y	2	Hmga1
A0A0R4J039	Histidine-rich glycoprotein	13	Hrg
P15864	Histone H1.2	14	Hist1h1c
P43277	Histone H1.3	3	Hist1h1d
Q60972	Histone-binding protein RBBP4	4	Rbbp4
Q9CQW9	Interferon-induced transmembrane protein 3	2	Ifitm3
Q61029	Lamina-associated polypeptide 2	12	Tmpo
Q9ERG0	LIM domain and actin-binding protein 1	16	Lima1
O09159	Lysosomal alpha-mannosidase	10	Man2b1
A0A1W2P711	Melanoma inhibitory activity protein 2	24	Mia2
A0A0R4J2D3;	Melanoma inhibitory activity protein 3	36	Mia3
O55022	Membrane-associated progesterone receptor component 1	19	Pgrmc1
Q9EQ20	Methylmalonate-semialdehyde dehydrogenase [acylating]	45	Aldh6a1
P27546	Microtubule-associated protein 4	9	Map4
A0A0R4J0N9	Microtubule-associated tumor suppressor 1 homolog	5	Mtus1
Q9WVA2	Mitochondrial import inner membrane translocase	9	Timm8a1

	subunit Tim8 A		
Q9WV98	Mitochondrial import inner membrane translocase subunit Tim9	5	Timm9
P62774	Myotrophin	7	Mtpn
Q9JHL1	Na(+)/H(+) exchange regulatory cofactor NHE-RF2;Na(+)/H(+) exchange regulatory cofactor NHE-RF	6	Slc9a3r2
Q9JIL4	Na(+)/H(+) exchange regulatory cofactor NHE-RF3	31	Pdzk1
Q8C5H8	NAD kinase 2, mitochondrial	3	Nadk2
Q9CQ75	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2	11	Ndufa2
Q9Z1P6	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7	14	Ndufa7
Q9DCJ5	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8	12	Ndufa8
Q9CQ54	NADH dehydrogenase [ubiquinone] 1 subunit C2	5	Ndufc2
P52503	NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial	8	Ndufs6
Q02819	Nucleobindin-1	41	Nucb1
P09405	Nucleolin	58	Ncl
Q61937	Nucleophosmin	27	Npm1
Q8CHP5	Partner of Y14 and mago	9	Wibg
P17742	Peptidyl-prolyl cis-trans isomerase A	22	Ppia
Q99KR7	Peptidyl-prolyl cis-trans isomerase F	15	Ppif
Q9D1M7	Peptidyl-prolyl cis-trans isomerase FKBP11	4	Fkbp11
P45878	Peptidyl-prolyl cis-trans isomerase FKBP2	15	Fkbp2
Q9QXS1	Plectin	30	Plec
O70591	Prefoldin subunit 2	9	Pfdn2
Q03958	Prefoldin subunit 6	11	Pfdn6
P49935	Pro-cathepsin H	12	Ctsh
D3Z7C6	Prostaglandin E synthase 3	7	Ptges3
Q9QXT0	Protein canopy homolog 2	17	Cnpy2
Q9DAU1	Protein canopy homolog 3	7	Cnpy3
Q9CR98	Protein FAM136A	16	Fam136a
Q80WJ7	Protein LYRIC	11	Mtdh
Q91XF0	Pyridoxine-5-phosphate oxidase	19	Pnpo
P97855	Ras GTPase-activating protein-binding protein 1	8	G3bp1
Q99PT1	Rho GDP-dissociation inhibitor 1	12	Arhgdia
P52760	Ribonuclease UK114	17	Hrsp12
Q9D1J3	SAP domain-containing ribonucleoprotein	8	Sarnp
E9Q3V6	Septin-2	10	2-Sep
Q9EP89	Serine beta-lactamase-like protein LACTB	5	Lactb
Q91VW3	SH3 domain-binding glutamic acid-rich-like protein 3	7	Sh3bgrl3
Q9CYR0	Single-stranded DNA-binding protein	8	Ssbp1
Q3V2H3	Sorting nexin-12	8	Snx12
Q9D8U8	Sorting nexin-5	15	Snx5

P16546	Spectrin alpha chain	1	Sptan1
Q62261	Spectrin beta chain	26	Sptbn1
Q60598	Src substrate cortactin	14	Cttn
Q9CQA3	Succinate dehydrogenase [ubiquinone] iron-sulfur subunit	20	Sdhb
Q9D5V6	Synapse-associated protein 1	4	Syap1
Q9CQU0	Thioredoxin domain-containing protein 12	11	Txndc12
Q9CQM5	Thioredoxin domain-containing protein 17	5	Txndc17
Q569Z6	Thyroid hormone receptor-associated protein 3	17	Thrap3
P39447	Tight junction protein ZO-1	14	Tjp1
P83940	Transcription elongation factor B polypeptide 1	6	Tceb1
Q64152	Transcription factor BTF3	7	Btf3
Q9CQH7	Transcription factor BTF3 homolog 4	7	Btf3l4
Q9QUI0	Transforming protein RhoA	13	Rhoa
P17751	Triosephosphate isomerase	32	Tpi1
P21107	Tropomyosin alpha-3 chain	4	Tpm3
P48428	Tubulin-specific chaperone A	12	Tbca
Q9CYZ2	Tumor protein D54	13	Tpd52l2
Q922Y1	UBX domain-containing protein 1	12	Ubxn1
Q9DCS2	UPF0585 protein C16orf13 homolog	10	
Q8BH80	Vesicle-associated membrane protein-associated protein B	16	Vapb
P20152	Vimentin	38	Vim
A0A2I3BRB9		2	
D3Z2H9		18	Tpm3-rs7
E9QA16		0	Cald1
F8WID5		1	Tpm1
Q3U422		9	Ndufv3

Table 3: List of Significantly Upregulated Proteins in Treated Male Mice

Protein IDs	Protein names	Unique peptides	Gene names
Q9CQV8	14-3-3 protein beta/alpha;14-3-3 protein beta/alpha, N-terminally processed	10	Ywhab
P62281	40S ribosomal protein S11	12	Rps11
P62274	40S ribosomal protein S29	6	Rps29
P62908	40S ribosomal protein S3	13	Rps3
P47963	60S ribosomal protein L13	21	Rpl13
P62717	60S ribosomal protein L18a	11	Rpl18a
P14115	60S ribosomal protein L27a	9	Rpl27a

P27659	60S ribosomal protein L3	18	Rpl3
Q9D8E6	60S ribosomal protein L4	35	Rpl4
P12970	60S ribosomal protein L7a	25	Rpl7a
Q8BGA8	Acyl-coenzyme A synthetase ACSM5, mitochondrial	25	Acsm5
G3X982	Aldehyde oxidase 3	28	Aox3
Q8VC28	Aldo-keto reductase family 1 member C13	3	Akr1c13
P22599	Alpha-1-antitrypsin 1-2	6	Serpina1b
O09174	Alpha-methylacyl-CoA racemase	23	Amacr
Q06185;Q8BTB6	ATP synthase subunit e, mitochondrial	14	Atp5i
O88696	ATP-dependent Clp protease proteolytic subunit, mitochondrial	11	Clpp
A0A3Q4L347	Cysteine dioxygenase type 1	5	Cdo1
Q9DBE0	Cysteine sulfinic acid decarboxylase	22	Csad
P99028	Cytochrome b-c1 complex subunit 6, mitochondrial	10	Uqcrh
Q62425	Cytochrome c oxidase subunit NDUFA4	9	Ndufa4
Q9D2G2	Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial	19	Dlst
Q9EQF5	Dihydropyrimidinase	32	Dpys
Q9D172	ES1 protein homolog, mitochondrial	24	D10Jhu81e
A0A494BB95	Eukaryotic translation initiation factor 1A, X-chromosomal;Eukaryotic translation initiation factor 1A	5	Eif1ax;Eif1a;Gm8300; Gm2016;Gm2056; Gm6803;Gm2035;Gm5039
Q8R1B4	Eukaryotic translation initiation factor 3 subunit C	14	Eif3c
Q6NZJ6	Eukaryotic translation initiation factor 4 gamma 1	30	Eif4g1
P05064	Fructose-bisphosphate aldolase A;Fructose-bisphosphate aldolase	23	Aldoa;Aldoart1
P97807	Fumarate hydratase, mitochondrial	30	Fh
P19157	Glutathione S-transferase P 1	22	Gstp1
O35969	Guanidinoacetate N-methyltransferase	6	Gamt
Q9D0E1	Heterogeneous nuclear ribonucleoprotein M	40	Hnrnpm
Q8VEK3	Heterogeneous nuclear ribonucleoprotein U	27	Hnrnpu
P10922	Histone H1.0;Histone H1.0, N-terminally processed	23	H1f0
P15864	Histone H1.2	14	Hist1h1c
P62806	Histone H4	15	Hist1h4a
Q9CXF0	Kynureninase	14	Kynu
Q61029	Lamina-associated polypeptide 2, isoforms beta/delta/epsilon/gamma;Lamina-	12	Tmpo

	associated polypeptide 2, isoforms alpha/zeta		
P21619	Lamin-B2	17	Lmnb2
Q61792	LIM and SH3 domain protein 1	18	Lasp1
A2CEL1	Major urinary protein 1	0	Mup1;Mup15
P11589	Major urinary protein 2	2	Mup2
Q3KQQ2	Major urinary protein 3	7	Mup3
Q60605	Myosin light polypeptide 6	12	Myl6
Q60817	Nascent polypeptide-associated complex subunit alpha;Nascent polypeptide-associated complex subunit alpha, muscle-specific form	7	Naca
P29595	NEDD8	5	Nedd8
P09405	Nucleolin	58	Ncl
Q9CY58	Plasminogen activator inhibitor 1 RNA-binding protein	17	Serbp1
P48678	Prelamin-A/C;Lamin-A/C	41	Lmna
Q6TCG2	Progestin and adipoQ receptor family member 9	5	Paqr9
O35955	Proteasome subunit beta type-10	5	Psmb10
Q8QZR3	Pyrethroid hydrolase Ces2a	16	Ces2a
Q9Z1Z2	Serine-threonine kinase receptor-associated protein	9	Strap
Q64442	Sorbitol dehydrogenase	35	Sord
Q9Z2I8	Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial	29	Suclg2
P21107	Tropomyosin alpha-3 chain	4	Tpm3
A0A0R4J0I1		6	
A0A0R4J135		3	Selenbp2
A2BIN1		0	Mup10
D3Z158		10	Qars
D3Z2H9		18	Tpm3-rs7

Table 4: List of Significantly Downregulated Proteins in Treated Male Mice

Protein IDs	Protein names	Unique peptides	Gene names
P62334	26S protease regulatory subunit 10B	19	Psmc6
O88685	26S protease regulatory subunit 6A	20	Psmc3
P26516	26S proteasome non-ATPase regulatory subunit 7	8	Psmd7
Q283N4	2-oxo-4-hydroxy-4-carboxy-5-	15	Urad

	ureidoimidazoline decarboxylase		
A2AFQ2	3-hydroxyacyl-CoA dehydrogenase type-2	16	Hsd17b10
Q99JY9	Actin-related protein 3	21	Actr3
A0A0R4J0I6	Acyl-CoA dehydrogenase family member 11	17	Acad11
J3QN31	Adenylosuccinate synthetase isozyme 1	5	Adssl1
P51881	ADP/ATP translocase 2;ADP/ATP translocase 2, N-terminally processed	28	Slc25a5
Q9CZS1	Aldehyde dehydrogenase X, mitochondrial	27	Aldh1b1
P17182	Alpha-enolase	50	Eno1
Q01339	Beta-2-glycoprotein 1	19	Apoh
P48758	Carbonyl reductase [NADPH] 1	26	Cbr1
O88587	Catechol O-methyltransferase	16	Comt
P10605	Cathepsin B;Cathepsin B light chain;Cathepsin B heavy chain	11	Ctsb
O55029	Coatomer subunit beta	9	Copb2
Q61129	Complement factor I;Complement factor I heavy chain;Complement factor I light chain	12	Cfi
Q9WUM3	Coronin-1B	16	Coro1b
Q9D855	Cytochrome b-c1 complex subunit 7	19	Uqcrb
P19783	Cytochrome c oxidase subunit 4 isoform 1, mitochondrial	19	Cox4i1
P12787	Cytochrome c oxidase subunit 5A, mitochondrial	10	Cox5a
P56391	Cytochrome c oxidase subunit 6B1	14	Cox6b1
Q9D0M3	Cytochrome c1, heme protein, mitochondrial	8	Cyc1
Q9R0P5	Destrin	11	Dstn
P63037	DnaJ homolog subfamily A member 1	8	Dnaja1
Q8BL66	Early endosome antigen 1	42	Eea1
P58252	Elongation factor 2	57	Eef2
Q9WUR2	Enoyl-CoA delta isomerase 2, mitochondrial	14	Eci2
Q9D7J9	Enoyl-CoA hydratase domain-containing protein 3, mitochondrial	8	Echdc3
Q05816	Fatty acid-binding protein, epidermal	24	Fabp5
E9PV24	Fibrinogen alpha chain;Fibrinopeptide A;Fibrinogen alpha chain	43	Fga
Q9Z1Z0	General vesicular transport factor	18	Uso1

	p115		
Q00612	Glucose-6-phosphate 1-dehydrogenase X;Glucose-6-phosphate 1-dehydrogenase	12	G6pdx
Q9DCM2	Glutathione S-transferase kappa 1	14	Gstk1
Q64471	Glutathione S-transferase theta-1	16	Gstt1
Q61133	Glutathione S-transferase theta-2	7	Gstt2
Q64521	Glycerol-3-phosphate dehydrogenase, mitochondrial;Glycerol-3-phosphate dehydrogenase	26	Gpd2
Q99LP6	GrpE protein homolog 1, mitochondrial	20	Grpel1
Q9WTP7	GTP:AMP phosphotransferase AK3, mitochondrial	28	Ak3
P63017	Heat shock cognate 71 kDa protein	52	Hspa8
P38060	Hydroxymethylglutaryl-CoA lyase, mitochondrial	22	Hmgcl
P40936	Indolethylamine N-methyltransferase	18	Inmt
A0A1L1STE6	Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial	14	Idh3a
O88844	Isocitrate dehydrogenase [NADP] cytoplasmic	50	Idh1
Q9Z2I0	LETM1 and EF-hand domain-containing protein 1, mitochondrial	19	Letm1
Q8VBT2	L-serine dehydratase/L-threonine deaminase	11	Sds
P70699	Lysosomal alpha-glucosidase	9	Gaa
Q6ZQI3	Malectin	4	Mlec
Q3ULD5	Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial	19	Mccc2
Q9EQ20	Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial	45	Aldh6a1
Q8CAQ8	MICOS complex subunit Mic60	10	Immt
P62075	Mitochondrial import inner membrane translocase subunit Tim13	9	Timm13
Q9D6Y7	Mitochondrial peptide methionine sulfoxide reductase	17	Msra
Q9JIL4	Na(+)/H(+) exchange regulatory cofactor NHE-RF3	31	Pdzk1
Q8C5H8	NAD kinase 2, mitochondrial	3	Nadk2
Q9CPP6	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5	8	Ndufa5
Q9JMD3	PCTP-like protein	11	Stard10

Q8CI51	PDZ and LIM domain protein 5	7	Pdlim5
P43883	Perilipin-2	25	Plin2
O70591	Prefoldin subunit 2	9	Pfdn2
Q91ZA3	Propionyl-CoA carboxylase alpha chain, mitochondrial	35	Pcca
Q9WVE8	Protein kinase C and casein kinase substrate in neurons protein 2	16	Pacsin2
Q3UM45	Protein phosphatase 1 regulatory subunit 7	11	Ppp1r7
P36993	Protein phosphatase 1B	1	Ppm1b
P21981	Protein-glutamine gamma-glutamyltransferase 2	20	Tgm2
E9Q509	Pyruvate kinase;Pyruvate kinase PKLR	53	Pklr
Q64374	Regucalcin	40	Rgn
Q9JLI6	Selenocysteine lyase	12	Scly
P50431	Serine hydroxymethyltransferase, cytosolic;Serine hydroxymethyltransferase	30	Shmt1
Q76MZ3	Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform	17	Ppp2r1a
Q99JR1	Sideroflexin-1	9	Sfxn1
Q9D8U8	Sorting nexin-5	15	Snx5
Q9CQA3	Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial	20	Sdhb
E9QNL5	Sulfotransferase	5	Sult1a1
P42932	T-complex protein 1 subunit theta	23	Cct8
Q9CQM5	Thioredoxin domain-containing protein 17	5	Txndc17
Q62264	Thyroid hormone-inducible hepatic protein	8	Thrsp
Q9CYZ2	Tumor protein D54	13	Tpd52l2
Q8K1Z0	Ubiquinone biosynthesis protein COQ9, mitochondrial	13	Coq9
P50544	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	31	Acadvl
Q8BH80	Vesicle-associated membrane protein-associated protein B	16	Vapb
Q8CC88	von Willebrand factor A domain-containing protein 8	10	Vwa8
A0A075B5N7		3	Igkv6-13
E9Q5K4		14	Cyp2c44
Q99L20		14	Gstt3